Menu
ETF
Annual · values202320222021202020192018
Operating Cash Flow-11.79 M USD-17.47 M USD-14.99 M USD-16.81 M USD-20.80 M USD-19.60 M USD
Depreciation & Amortization677000 USD837000 USD701000 USD632000 USD223000 USD152000 USD
Stock-Based Compensation
Capital Expenditures-104000 USD-224000 USD-470000 USD-88000 USD-468000 USD-547000 USD
Cash Flow from Investing
Cash Flow from Financing
Dividends Paid
Stock Buybacks-12000 USD-11000 USD0 USD
Free Cash Flow-11.30 M USD-17.69 M USD-14.89 M USD-17.08 M USD-20.38 M USD-15.48 M USD

Motus GI Holdings Inc. is a medical technology company focused on enhancing clinical outcomes in gastrointestinal diagnostics. The company's primary innovation is the Pure-Vu System, a device designed to facilitate the cleaning of the gastrointestinal tract during colonoscopy and upper endoscopy procedures. The Pure-Vu System integrates seamlessly with standard gastroscopes and colonoscopes, allowing endoscopists to efficiently cleanse inadequately prepared colons intra-procedurally, thereby improving visualization and the overall quality of the exam. By supporting better cleansing, the system aims to minimize delays and incomplete procedures, which are significant challenges in inpatient colonoscopy. Motus GI Holdings Inc. addresses unmet needs in endoscopy by improving procedural efficiency, reducing hospital costs, and supporting better patient outcomes. Headquartered in Fort Lauderdale, Florida, and with subsidiaries in the U.S. and Israel, the company serves hospitals and healthcare providers seeking effective and cost-efficient solutions for gastrointestinal diagnostics.